Cell and Gene Therapy Tools and Reagents are the special products and materials that scientists and researchers use to develop and improve treatments based on cell and gene therapies. These therapies aim to treat or cure diseases by altering a person’s cells or genes.
Here’s how they work:
Cell Therapy: Involves using healthy cells to replace or repair damaged ones. For example, stem cells can be used to help regenerate tissues or repair organs.
Gene Therapy: Aims to treat genetic diseases by changing or repairing the genes inside a person’s cells. It can involve adding new genes or fixing the ones that are causing problems.
To make these therapies work, researchers need tools (like special machines) and reagents (chemical substances, like growth factors or viruses) to help grow cells, deliver genes, or monitor progress. These tools and reagents help ensure that cells are grown in the right conditions and that the gene-editing process is done accurately.
In simple terms, tools and reagents are like the ingredients and equipment you need to cook up a recipe—except in this case, the recipe is for making new treatments that could cure diseases!
According to BCC Research, the global market for Cell and Gene Therapy Tools, and Reagents: Global Markets is showing remarkable growth, driven by several key factors. As of 2024, the market was valued at approximately $10.0 billion and is projected to grow to $16.7 billion by 2029, reflecting a compound annual growth rate (CAGR) of 10.8%.
Leading Cell & Gene Therapy Companies by Revenue
- Roche Holding based in Switzerland, is a global healthcare company with US$64.16 billion in revenue. It operates in two main divisions: Pharmaceuticals and Diagnostics. Since its founding in 1896, Roche has been a pioneer in healthcare, introducing many successful drugs. The company has extensive experience in cell and gene therapy, offering solutions to overcome challenges in manufacturing advanced treatments. Roche supports the entire development process, from cell isolation to quality control. In 2020, Roche acquired Spark Therapeutics for US$4.3 billion to expand its gene therapy capabilities for various diseases.
- Novartis AG is a leading Swiss multinational pharmaceutical company with a revenue of US$51.6 billion. It has two main divisions: Novartis Gene Therapy and Novartis Oncology. In 2018, Novartis acquired AveXis for $8.7 billion, which became Novartis Gene Therapies, focusing on developing gene therapies for rare genetic diseases, especially those affecting the nervous system. The company is working on 162 clinical projects and offers a Managed Access Program to provide unapproved treatments to eligible patients.
In 2020, Novartis acquired Vedere Bio, a company focused on vision restoration gene therapy, and in 2021, it purchased Gyroscope Therapeutics for $1.5 billion to enhance its gene therapy portfolio, including treatments for eye diseases like geographic atrophy.
- Sarepta Therapeutics Inc., is a Massachusetts-based company with US$701.9 million in revenue, focused on developing RNA-targeted medicines for rare diseases. Its main products use Morpholino oligomers, which help treat conditions like Duchenne muscular dystrophy (DMD) through antisense therapy. Approved drugs include Exondys 51, Vyondys 53, and Amondys 45 for DMD patients with specific gene mutations. Sarepta's pipeline targets DMD, limb-girdle muscular dystrophies, and other neuromuscular and CNS disorders. The company's gene therapy platform is designed to develop new treatments for serious diseases.
- REGENXBIO Inc is a clinical-stage biotechnology company with US$470.3 million in revenue. It focuses on gene therapy to treat genetic diseases, using its proprietary NAV Technology Platform to develop AAV vectors that help the body produce therapeutic proteins. Its leading treatment, RGX-134, is in Phase III trials for wet age-related macular degeneration. REGENXBIO also licenses its technology to other companies in the pharmaceutical and biotechnology sectors.
- Spark Therapeutics is a leading gene therapy developer founded in 2013, with US$64.7 million in revenue. The company focuses on revolutionizing the treatment of genetic diseases. In 2017, it became the first to commercialize a gene therapy for an inherited disease, Luxturna, for retinal dystrophy. Acquired by Roche in 2019, Spark operates as an independent subsidiary. It is now developing gene therapies for neurological conditions like Huntington's disease, Pompe disease, and Stargardt disease, which causes vision loss in children and young adults.
Learn More and Take Action:
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.
Contact us today to find out more.
